busulfan has been researched along with Medulloblastoma in 11 studies
Medulloblastoma: A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We previously demonstrated that Busulfan-Thiotepa (Bu-Thio) and ASCT effectively treated patients with locally relapsed medulloblastoma after surgery and conventional chemotherapy." | 9.11 | High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy. ( Benhamou, E; Couanet, D; Fillipini, B; Grill, J; Habrand, JL; Hartmann, O; Kalifa, C; Valteau-Couanet, D, 2005) |
| "The aim of the study is to evaluate the outcome of young children with high risk localized medulloblastomas (newly diagnosed classical or incompletely resected) treated by high-dose busulfan-thiotepa with autologous stem cell rescue (ASCT) followed by focal radiation therapy (RT)." | 7.80 | High-dose busulfan-thiotepa with autologous stem cell transplantation followed by posterior fossa irradiation in young children with classical or incompletely resected medulloblastoma. ( Bergthold, G; Dhermain, F; Dufour, C; El Kababri, M; Goma, G; Grill, J; Kieffer, V; Raquin, MA; Sainte-Rose, C; Valteau-Couanet, D; Varlet, P, 2014) |
| "The aim of this in-vitro study was to evaluate the combination of busulfan with radiotherapy on TE-671 human medulloblastoma cells since unexpected clinical toxicity of busulfan was reported during the treatment of brain tumors, suggesting a possible radiopotentiation." | 7.68 | In vitro combination of high dose busulfan with radiotherapy on medulloblastoma cells: additive effect without potentiation. ( Bey, P; Chastagner, P; Marchal, C; Merlin, JL; Weber, B, 1991) |
| "We previously demonstrated that Busulfan-Thiotepa (Bu-Thio) and ASCT effectively treated patients with locally relapsed medulloblastoma after surgery and conventional chemotherapy." | 5.11 | High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy. ( Benhamou, E; Couanet, D; Fillipini, B; Grill, J; Habrand, JL; Hartmann, O; Kalifa, C; Valteau-Couanet, D, 2005) |
| "The aim of the study is to evaluate the outcome of young children with high risk localized medulloblastomas (newly diagnosed classical or incompletely resected) treated by high-dose busulfan-thiotepa with autologous stem cell rescue (ASCT) followed by focal radiation therapy (RT)." | 3.80 | High-dose busulfan-thiotepa with autologous stem cell transplantation followed by posterior fossa irradiation in young children with classical or incompletely resected medulloblastoma. ( Bergthold, G; Dhermain, F; Dufour, C; El Kababri, M; Goma, G; Grill, J; Kieffer, V; Raquin, MA; Sainte-Rose, C; Valteau-Couanet, D; Varlet, P, 2014) |
| "We evaluated the antitumor activity of busulfan against a panel of tumor cell lines and xenografts in athymic nude mice derived from childhood high-grade glioma, adult high-grade glioma, ependymoma, and medulloblastoma." | 3.69 | Busulfan therapy of central nervous system xenografts in athymic mice. ( Aaron, RH; Bigner, DD; Colvin, OM; Elion, GB; Friedman, HS; Graham, M; Keir, S, 1994) |
| "The aim of this in-vitro study was to evaluate the combination of busulfan with radiotherapy on TE-671 human medulloblastoma cells since unexpected clinical toxicity of busulfan was reported during the treatment of brain tumors, suggesting a possible radiopotentiation." | 3.68 | In vitro combination of high dose busulfan with radiotherapy on medulloblastoma cells: additive effect without potentiation. ( Bey, P; Chastagner, P; Marchal, C; Merlin, JL; Weber, B, 1991) |
| " The highest bioavailability was obtained with busulphan in DMSO administered i." | 1.30 | Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations. ( Boland, I; Gouyette, A; Hartmann, O; Kalifa, C; Morizet, J; Terrier-Lacombe, MJ; Valteau-Couanet, D; Vassal, G, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (45.45) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bergthold, G | 1 |
| El Kababri, M | 1 |
| Varlet, P | 1 |
| Dhermain, F | 1 |
| Sainte-Rose, C | 2 |
| Raquin, MA | 2 |
| Kieffer, V | 1 |
| Goma, G | 1 |
| Grill, J | 3 |
| Valteau-Couanet, D | 4 |
| Dufour, C | 1 |
| Nishikawa, T | 1 |
| Okamoto, Y | 1 |
| Tanabe, T | 1 |
| Shinkoda, Y | 1 |
| Kodama, Y | 1 |
| Higashi, M | 1 |
| Hirano, H | 1 |
| Arita, K | 1 |
| Kawano, Y | 1 |
| Pérez-Martínez, A | 1 |
| Lassaletta, A | 1 |
| González-Vicent, M | 1 |
| Sevilla, J | 1 |
| Díaz, MA | 1 |
| Madero, L | 1 |
| Fillipini, B | 1 |
| Benhamou, E | 2 |
| Kalifa, C | 4 |
| Couanet, D | 1 |
| Habrand, JL | 2 |
| Hartmann, O | 3 |
| Ridola, V | 1 |
| Doz, F | 2 |
| Gentet, JC | 1 |
| Frappaz, D | 1 |
| Aaron, RH | 1 |
| Elion, GB | 1 |
| Colvin, OM | 1 |
| Graham, M | 1 |
| Keir, S | 1 |
| Bigner, DD | 1 |
| Friedman, HS | 2 |
| Graham, ML | 1 |
| Herndon, JE | 1 |
| Casey, JR | 1 |
| Chaffee, S | 1 |
| Ciocci, GH | 1 |
| Krischer, JP | 1 |
| Kurtzberg, J | 1 |
| Laughlin, MJ | 1 |
| Longee, DC | 1 |
| Olson, JF | 1 |
| Paleologus, N | 1 |
| Pennington, CN | 1 |
| Dupuis-Girod, S | 1 |
| Mechinaud, F | 1 |
| Bouffet, E | 1 |
| Coze, C | 1 |
| Boland, I | 1 |
| Vassal, G | 1 |
| Morizet, J | 1 |
| Terrier-Lacombe, MJ | 1 |
| Gouyette, A | 1 |
| Foa, C | 1 |
| Magné, N | 1 |
| Bondiau, PY | 1 |
| Otto, J | 1 |
| Thyss, A | 1 |
| Merlin, JL | 1 |
| Chastagner, P | 1 |
| Marchal, C | 1 |
| Weber, B | 1 |
| Bey, P | 1 |
1 review available for busulfan and Medulloblastoma
| Article | Year |
|---|---|
[High-dose chemotherapy in relapse of medulloblastoma in young children].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cerebellar Ne | 1997 |
2 trials available for busulfan and Medulloblastoma
| Article | Year |
|---|---|
High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cerebel | 2005 |
High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combi | 2005 |
8 other studies available for busulfan and Medulloblastoma
| Article | Year |
|---|---|
High-dose busulfan-thiotepa with autologous stem cell transplantation followed by posterior fossa irradiation in young children with classical or incompletely resected medulloblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cerebellar Neoplasms; Child, Preschool; Co | 2014 |
Unexpectedly high AUC levels in a child who received intravenous busulfan before stem cell transplantation.
Topics: Area Under Curve; Busulfan; Cerebellar Neoplasms; Child; Drug Monitoring; Fatal Outcome; Glutathione | 2010 |
High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Busulfan; Cerebellar Neoplasms; Child | 2007 |
Busulfan therapy of central nervous system xenografts in athymic mice.
Topics: Animals; Brain Neoplasms; Busulfan; Child, Preschool; Cyclophosphamide; Female; Humans; Injections, | 1994 |
High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brai | 1997 |
Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations.
Topics: Administration, Oral; Animals; Biological Availability; Brain Neoplasms; Busulfan; Carboxymethylcell | 1999 |
High-dose chemotherapy with autologous stem cell support in an adult with bone marrow relapse of medulloblastoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Busulfan; Carboplatin; | 2000 |
In vitro combination of high dose busulfan with radiotherapy on medulloblastoma cells: additive effect without potentiation.
Topics: Busulfan; Cell Line; Cerebellar Neoplasms; Colony-Forming Units Assay; Combined Modality Therapy; Hu | 1991 |